You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

“Yes! We Can End TB." World TB Day is March 24, 2023. Join us in the fight.

Cepheid expanded its breast cancer diagnostics capabilities with the acquisition of OncoMark, a company that developed technology to estimate the likelihood of early-stage breast cancer recurrence after treatment.  Optimized to run on the Cepheid GeneXpert® systems, the technology uses a proprietary algorithm to produce a binary risk score (high risk vs low risk) to predict the likelihood of disease recurrence in the next 10 years.  

Cepheid also continues to offer the Xpert® Breast Cancer STRAT4 biomarker test in countries accepting the CE-IVD mark.

To learn more, contact the Cepheid Medical and Scientific Affairs and Strategy team for Oncology at:

Xpert Breast Cancer STRAT-4 is not available in the US.

With Cepheid’s proven “lab in a cartridge,” our tests give patients and their doctors peace of mind when it matters most. The pioneering mindset of our oncology team is bolstered by Cepheid’s strong molecular biology capabilities, extensive global infrastructure, and an unwavering commitment to scientific rigor.

Xpert BCR-ABL Ultra Resources:

Xpert Breast Cancer STRAT4* Resources:


In Here, We are Defining a New
Era of Cancer Diagnostics

More than a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics with the GeneXpert® System. The complicated process of nucleic acid extraction, amplification and detection is all carried out within each single use cartridge. By making complex technology easy to use, our GeneXpert® cartridge has become the symbol of the Molecular Revolution. Using advanced microfluidics, all aspects of the testing process are handled within the cartridge chambers, minimizing the risk of cross contamination. Each cartridge is standardized and comes with internal controls, making running extra standard curves obsolete.

Our oncology tests quickly and accurately characterize multiple cancer markers using the same game changing system.


1. Based on July 2019 market research conducted by Kalorama Information with sample respondents in select countries.
2. CE IVD and US-IVD. In Vitro Diagnostic Medical Device. Not available in all countries.
3. CE IVD. In Vitro Diagnostic Medical Device. Not available in all counties. Not available in the United States.

Back to Top